“Was Sexism Really Responsible for the FDA’s Hesitancy to Sign Off on Flibanserin?”


“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?

Article →

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time